Vipin K Garg
CIK 1515813 · President and CEO · last filed 2026-02-02
Vipin K Garg is a President and CEO who has filed 68 SEC Form 4 insider transactions across 3 companies since 2011. The most recent filing, for ALT, was dated Feb 2, 2026. Across all open-market trades the lifetime net is −$584.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $955.0K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
910 CLOPPER ROAD, SUITE 201S
GAITHERSBURG, MD 20878
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALT | President and CEO | 429,225 | $2.23 | $955.0K | -$584.2K | 57 | 2026-02-02 |
| Neos Therapeutics, Inc. (NEOS) Delisted | Chief Executive Officer | 160,748 | $1.15 | $184.9K | $0 | 9 | 2018-03-05 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | President & CEO | — | — | — | $0 | 2 | 2012-08-09 |
Recent Filings
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-02 | ALT | Mixed | +22,069 | -$43.9K | EDGAR |
| 2026-01-29 | ALT | Mixed | +23,302 | -$110.6K | EDGAR |
| 2026-01-27 | ALT | Mixed | +24,066 | -$98.9K | EDGAR |
| 2025-02-03 | ALT | Mixed | +39,161 | -$163.6K | EDGAR |
| 2025-01-28 | ALT | Mixed | +23,893 | -$126.7K | EDGAR |
| 2024-02-05 | ALT | Mixed | +19,806 | -$150.3K | EDGAR |
| 2024-02-01 | ALT | Mixed | +22,967 | -$93.4K | EDGAR |
| 2024-01-29 | ALT | Grant (A) | — | $0 | EDGAR |
| 2023-08-02 | ALT | Grant (A) | +126 | $354 | EDGAR |
| 2023-02-06 | ALT | Mixed | +10,528 | -$126.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.